Department of Anesthesia and Intensive Care, Parma University Hospital, Parma, Italy.
University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble Institute Neurosciences, Grenoble, France.
J Neurosurg Anesthesiol. 2024 Jul 1;36(3):258-265. doi: 10.1097/ANA.0000000000000923. Epub 2023 May 26.
Cerebral infarction from delayed cerebral ischemia (DCI) is a leading cause of poor neurological outcome after aneurysmal subarachnoid hemorrhage (aSAH). We performed an international clinical practice survey to identify monitoring and management strategies for cerebral vasospasm associated with DCI in aSAH patients requiring intensive care unit admission.
The survey questionnaire was available on the European Society of Intensive Care Medicine (May 2021-June 2022) and Neurocritical Care Society (April - June 2022) websites following endorsement by these societies.
There were 292 respondents from 240 centers in 38 countries. In conscious aSAH patients or those able to tolerate an interruption of sedation, neurological examination was the most frequently used diagnostic modality to detect delayed neurological deficits related to DCI caused by cerebral vasospasm (278 respondents, 95.2%), while in unconscious patients transcranial Doppler/cerebral ultrasound was most frequently used modality (200, 68.5%). Computed tomography angiography was mostly used to confirm the presence of vasospasm as a cause of DCI. Nimodipine was administered for DCI prophylaxis by the majority of the respondents (257, 88%), mostly by an enteral route (206, 71.3%). If there was a significant reduction in arterial blood pressure after nimodipine administration, a vasopressor was added and nimodipine dosage unchanged (131, 45.6%) or reduced (122, 42.5%). Induced hypertension was used by 244 (85%) respondents as first-line management of DCI related to vasospasm; 168 (59.6%) respondents used an intra-arterial procedure as second-line therapy.
This survey demonstrated variability in monitoring and management strategies for DCI related to vasospasm after aSAH. These findings may be helpful in promoting educational programs and future research.
迟发性脑缺血(DCI)引起的脑梗死是蛛网膜下腔出血(aSAH)后神经功能预后不良的主要原因。我们进行了一项国际临床实践调查,以确定需要入住重症监护病房的 aSAH 患者中与 DCI 相关的脑血管痉挛的监测和管理策略。
该调查问卷调查表于 2021 年 5 月至 2022 年 6 月可在欧洲重症监护医学学会(ESICM)和神经重症监护学会(Neurocritical Care Society,NCS)网站上获取,获取前获得了这两个学会的认可。
来自 38 个国家 240 个中心的 292 名受访者参与了调查。在意识清醒的 aSAH 患者或能够耐受镇静中断的患者中,神经检查是最常用来诊断与脑血管痉挛引起的 DCI 相关的迟发性神经功能缺损的诊断方法(278 名受访者,95.2%),而在无意识患者中,经颅多普勒/脑超声是最常使用的方法(200 名,68.5%)。计算机断层血管造影术(computed tomography angiography,CTA)主要用于确认血管痉挛是 DCI 的原因。大多数受访者(257 名,88%)使用尼莫地平预防 DCI,主要通过肠内途径(206 名,71.3%)。如果尼莫地平给药后动脉血压显著下降,会添加血管加压药且不改变(131 名,45.6%)或减少(122 名,42.5%)尼莫地平剂量。244 名(85%)受访者将诱导性高血压作为血管痉挛相关性 DCI 的一线治疗方法;168 名(59.6%)受访者将动脉内治疗作为二线治疗方法。
该调查显示,蛛网膜下腔出血后与血管痉挛相关的 DCI 的监测和管理策略存在差异。这些发现可能有助于促进教育计划和未来的研究。